EUVIMEDEUVIMED entdecken
Crossref

Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when

Sylvia Drazilova, Peter Jarcuska, Tomas Koky, Martin Harhovsky, Slavomira Komarova, Jan Vasil, Martin Janicko

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.121491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Sylvia Drazilova und 6 weiteren Autor:innen. Die Arbeit nennt 120 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ursodeoxycholic acid (UDCA) is the first-line treatment of primary biliary cholangitis (PBC). Approximately two-thirds of patients have a biochemical response to UDCA, but only one-third of treated patients achieve a complete biochemical response. UDCA nonresponse is associated with hepatic decompensation and higher liver-related mortality; therefore, UDCA nonresponders should be considered for second-line PBC treatment. Nonfibrate peroxisome proliferator-activated receptor (PPAR) agonists elafibranor and seladelpar are approved for second-line PBC treatment in UDCA nonresponders and in UDCA treatment intolerance. Fibrates are an alternative second-line PBC therapy, but they are not approved for second-line treatment. A significant benefit of PPAR receptor agonists therapy is the alleviation of pruritus in some patients. Second-line PBC treatment is usually indicated after 1 year of UDCA therapy; however, it may be considered after 6 months of UDCA treatment in high-risk PBC patients. The selection of drug for second-line PBC treatment and the timing of therapy initiation should be individualized. Many factors, including PBC complications, especially pruritus, should also be considered in the decision-making algorithm. It will be necessary in the coming years to evaluate the efficacy of PPAR agonists in real-world clinical practice, including monitoring the incidence of decompensated liver cirrhosis and liver-related mortality.

Zitieren

APA

Drazilova, S., Jarcuska, P., Koky, T., Harhovsky, M., Komarova, S., Vasil, J., & Janicko, M. (2026). Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.121491

Vancouver

Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, et al. Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.121491

BibTeX
@article{Drazilova2026,
  author = {Drazilova, Sylvia and Jarcuska, Peter and Koky, Tomas and Harhovsky, Martin and Komarova, Slavomira and Vasil, Jan and Janicko, Martin},
  title = {Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.121491}
}
Kostenlos starten →